KCT0002159招募中未知
A prospective, randomized, open-label, multicenter, parallel design, phase III study to assess the efficacy and safety of GV1001 concurrent with Gemcitabine/Capecitabine versus Gemcitabine/Capecitabine alone in treating locally advanced and metastatic pancreatic cancer patients
Samsung Pharmaceutical0 个研究点目标入组 148 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 148
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Age = 19 years
- •2. Histologically or cytologically proven pancreatic ductal adenocarcinoma carcinoma or undifferentiated carcinoma of the pancreas.
- •3. Locally advanced or metastatic disease precluding curative surgical resection or patients who have relapsed following previously resected pancreatic cancer.
- •4. Contrast enhanced CT scan of the thorax, abdomen and pelvis within 28 days (and up to a maximum of 32 days) prior to commencing treatment.
- •5. Unidimensionally measurable disease (from CT scan) in accordance with the RECIST guidelines.
- •6. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
- •7. Adequate organ function as determined by the following laboratory values:
- •?Platelets =100 x 10^9 /L
- •?WBC = 3 x 10^9 /L
- •?ANC =1.5 x 10^9 /L
- •?Serum total bilirubin = 2.0 mg/dL
- •?CCr (Cockcroft & Gault) > 50 mL/min
- •8. Life expectancy = 90 days
- •9. Fully informed written consent given.
排除标准
- •1. Brain metastasis or meningeal carcinomatosis.
- •2. Clinically significant serious disease or organ system disease not currently controlled on present therapy.
- •3. Previous chemotherapy for locally advanced and metastatic disease. Previously adjuvant chemotherapy for resected pancreatic cancer will be permitted providing chemotherapy was completed more than 12 months previously.
- •4. Radiotherapy within the last 8 weeks prior to start of study treatment.
- •5. Concurrent malignancies or invasive cancers diagnosed within the past 5 years except for adequately treated basal cell carcinoma of the skin, in situ carcinoma of the uterine cervix or resected pancreatic cancer.
- •6. Medication which might affect immunocompetence e.g. chronic treatment with long term steroids or other immunosuppressant for an unrelated condition. Patients will be eligible if they have been receiving short term steroids for palliation of cancer related symptoms.
- •7. Administration of medicines from other clinical trials within 8 weeks from registration.
- •8. Pregnancy or breast feeding.
- •9.Uncontrolled angina pectoris.
- •10.Known malabsorption syndromes.
- •11.Patients with a known hypersensitivity to any of the investigational products or patients with a dihydropyrimidine dehydrogenase (DPD) deficiency.
- •12.All men or women of reproductive potential, unless using at least two contraceptive precautions, one of which must be a condom.
- •13.Investigator's judgment against participation in the study
研究者
相似试验
进行中（未招募）
1 期
A comparison of pre-surgical combination of trastuzumab and pertuzumab with concurrent taxane chemotherapy or endocrine therapy given for twelve weeks with a quality of life assessment of trastuzumab, pertuzumab in combination with standard (neo)adjuvant treatment in patients with operable HER2+/HR+ breast cancer.EUCTR2016-005157-21-DEPalleos healthcare GmbH259
招募中
不适用
A phase 2 study to evaluate safety and efficacy of autologous dendritic cell in Combination With TACE, in Treatment of Patients With unresectable hepatocellular carcinomaNeoplasmsKCT0000986Kyungpook National University Hospital40
进行中（未招募）
不适用
A multi-center, randomized, open-label, prospective bridging, parallel dosefinding trial comparing efficacy, safety and pharmacokinetics of 4 doses of Org 25969 and placebo administered at reappearance of T2 after rocuronium or vecuronium in Japanese and Caucasian subjects. Part B: Caucasian subjects.ot applicableEUCTR2005-001133-15-DEV Organon100
进行中（未招募）
不适用
A multi-center, randomized, open-label, prospective bridging, parallel dosefinding trial comparing efficacy, safety and pharmacokinetics of 4 doses of Org 25969 and placebo administered at reappearance of T2 after rocuronium or vecuronium in Japanese and Caucasian subjects. Part B: Caucasian subjects.EUCTR2005-001133-15-SEV Organon100
进行中（未招募）
不适用
A multi-center, randomized, open-label, prospective bridging, parallel dosefinding trial comparing efficacy, safety and pharmacokinetics of 4 doses of Org 25969 and placebo administered at reappearance of T2 after rocuronium or vecuronium in Japanese and Caucasian subjects. Part B: Caucasian subjects.ot applicableEUCTR2005-001133-15-BEV Organon100